Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis

Journal of Drugs in Dermatology

Volumn 8, Issue 12, 2009, Pages 1106-1111

  Sugarman, Jeffrey L ^a   Parish, Lawrence Charles ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; EPICERAM; FLUTICASONE PROPIONATE; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; CHOLESTEROL; FATTY ACID; FLUTICASONE;

ARTICLE; ATOPIC DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRURITUS; SHORT COURSE THERAPY; SLEEP PATTERN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MULTICENTER STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADOLESCENT; ANDROSTADIENES; CERAMIDES; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; DERMATITIS, ATOPIC; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INFANT; MALE; SINGLE-BLIND METHOD;

EID: 74049086065     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bos JD, Van Leent EJ, Sillevis Smitt JH. The millennium criteria for the diagnosis of atopic dermatitis. Exp Dermatol. 1998;7(4):132-138. (Pubitemid 28419400)
2. Boguniewicz M, Schmid-Grendelmeier P, Leung DY. Atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):40-43. (Pubitemid 43946486)
3. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657. (Pubitemid 38544154)
4. Taieb A. Hypothesis: From epidermal barrier dysfunction to atopic disorders. Contact Dermatitis. 1999; 41(4):177-180.
5. Elias PM, Wood LC, Feingold KR. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat. 1999;10(3):119-126. (Pubitemid 29416060)
6. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. J Allergy Clin Immunol. 2006;118(1):3-21. (Pubitemid 43946484)
7. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient's opinion. Br J Dermatol. 2007;157(1):142-148. (Pubitemid 46934268)
8. Weischer M, Rocken M, Berneburg M. Calcineurin inhibitors and rapamycin: Cancer protection or promotion? Exp Dermatol. 2007;16:385-393. (Pubitemid 46585366)
9. Lubbe J, Pournaras CC, Saurat JH. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology. 2000;201(3):249-251.
10. Stern RS. Topical calcineurin inhibitors labeling: Putting the "box" in perspective. Arch Dermatol. 2006;142(9):1233-1235.
11. Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Med Gen Med. 2006;8:8.
12. Proksch E, Folster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci. 2006;43(3):159-169. (Pubitemid 44189201)
13. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47(2):198-208.
14. Sugarman JL, Fluhr JW, Fowler AJ, et al. The objective severity assessment of atopic dermatitis score: An objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol. 2003;139(11):1417-1422. (Pubitemid 37433131)
15. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-446.
16. Sandilands A, O'Regan GM, Liao H, et al. Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest Dermatol. 2006;126(8):1770-1775. (Pubitemid 44086511)
17. Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006;118(1):214-219. (Pubitemid 43949588)
18. Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol. 1998;78(1):27-30. (Pubitemid 28103674)
19. Hudson TJ. Skin barrier function and allergic risk. Nat Genet. 2006;38(4):399-400.
20. Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as three months. J Am Acad Dermatol. 2002;46(3):387-393. (Pubitemid 34225403)
21. Cork MJ, Britton J, Butler L, et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol. 2003;149(3):582-589. (Pubitemid 37281592)
22. Mao-Qiang M, Brown BE, Wu-Pong S, et al. Exogenous non-physiologic versus physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol. 1995;131:809-816.
23. Nickoloff BJ, Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol. 1994;30(4):535-546. (Pubitemid 24121751)
24. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337-1343.
25. Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: A study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol. 1995;75(6):429-433. (Pubitemid 26051887)